Novartis’ Reclast Gains Paget’s Approval, But Still Waiting On Osteoporosis
Executive Summary
Novartis' Paget's disease treatment Reclast (zoledronic acid) will launch with an apparent pricing advantage over the current standard of care, Proctor & Gamble's Actonel (risedronate)
You may also be interested in...
Novartis Adds Osteoporosis Claim For Reclast, Plans Prevention Filing By Year End
Novartis plans to file an osteoporosis prevention claim for Reclast (zoledronic acid) by the end of 2007, the company told "The Pink Sheet" after the bisphosphonate's Aug. 17 approval for osteoporosis treatment. The Swiss firm will seek an indication for prevention of clinical fractures after hip fracture in both men and women
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.